Clinical Trial Update: A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating two fixed doses of brexpiprazole for agitation in Alzheimer's disease; completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agitation
• Alzheimer Disease

Drugs mentioned

• brexpiprazole (brexpiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Agitation Associated With, Alzheimer's Disease | Phase 3 | Status: COMPLETED | Results posted: 2020-06-16